E-Mail
Cancer biologists at Weill Cornell Medicine have been awarded a 2021 Top 10 Clinical Research Achievement Award from the Clinical Research Forum for their study last year describing a highly sensitive blood test for monitoring cancer progression and relapse.
The findings, entitled Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring, were published June 1 in
Nature Medicine by a team led by Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. Dr. Asaf Zviran, a postdoctoral researcher in the Landau lab during the study, was the paper s first author.
Date Time
Tumor microenvironment helps aggressive lymphomas
The environment surrounding the cancerous cells of a lymphoma tumor has a strong influence on the progression of these blood-cell cancers and their responses to therapies, according to a new study by Weill Cornell Medicine investigators.
Measuring this molecular and cellular environment, or “microenvironment,” appears to represent a new type of precision-medicine approach to lymphoma classification and treatment. CoRus13/Creative Commons
Diffuse large B-cell lymphoma.
The team analyzed the patterns of gene activity in tumor samples taken from the lymph nodes of thousands of lymphoma patients. They found that the cells within these tumors, which include both cancer cells and healthy cells, produce molecules that collectively constitute a distinct microenvironment for the tumors, influencing their biology and growth.
Date Time
Gene critical to immune cell development identified
Much of the three-dimensional architecture of the genome in antibody-producing immune cells is dependent on a gene called SMC3. When this gene is not working properly it can lead to improper immune cell development and to cancer, by disrupting how DNA is structured inside the cell nucleus, according to a team of researchers from Weill Cornell Medicine. Victoria Béguelin/Provided
The two canvases represent the genome as folded in cells with normal (left) or reduced levels of SMC3. The normal canvas is highly structured and functional, while the other canvas has lost its pattern and has open threads.
New maintenance treatment for AML shows strong benefit for patients
Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites.
This is the first time a maintenance treatment for AML has shown such a strong benefit for patients, and it is already being adopted as part of standard care.
New Treatment Prolongs Lives of Patients With Acute Myeloid Leukemia by Colleen Fleiss on January 23, 2021 at 11:31 PM
In patients with acute myeloid leukemia (AML), administering the cancer drug azacitidine as a maintenance treatment had improved overall survival, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites.
This is the first time a maintenance treatment for AML has shown such a strong benefit for patients, and it is already being adopted as part of standard care.
The results, which were published Dec. 24 in the New England Journal of Medicine, led to the U.S. Food and Drug Administration s approval in September 2020 of oral azacitidine, known by the trade name Onureg, as a maintenance therapy for AML.